TARGET ENHANCEMENT STAINS FOR ATHEROMATOUS PLAQUE

Information

  • Research Project
  • 3500887
  • ApplicationId
    3500887
  • Core Project Number
    R43HL036516
  • Full Project Number
    1R43HL036516-01
  • Serial Number
    36516
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/1986 - 39 years ago
  • Project End Date
    11/30/1986 - 38 years ago
  • Program Officer Name
  • Budget Start Date
    4/1/1986 - 39 years ago
  • Budget End Date
    11/30/1986 - 38 years ago
  • Fiscal Year
    1986
  • Support Year
    1
  • Suffix
  • Award Notice Date
    -
Organizations

TARGET ENHANCEMENT STAINS FOR ATHEROMATOUS PLAQUE

Laser angioplasty for atheromatous plaque is a promising surgical technique for ablation of obstructing atheromas of the main arteries with restoration of the blood flow. This technique is based on visualization and laser vaporization of plaque through fiber optic catheters. Without specific staining, it is difficult to accurately visualize the plaque through an angioscope and to consequently optimize either the direction or duration of laser irradiation. Due primarily to lack of specificity or sensitivity or to toxicity, the current experimental dyes limit future growth of laser ablation of atheroma, a technique that appears to have outstanding potential as a routine and commonly performed surgical procedure if suitable stains can be found. In collaboration with Dr. Murphy-Chutorian of Stanford, Molecular Probes has started a program to synthesize and evaluate fluorescent target enhancement stains for plaque. Desired characteristics sought are: selectivity for staining plaque versus normal vessel wall, useful speed and duration of staining, sensitivity of detection, suitable spectral properties, ability to destroy plaque under laser irradiation, low toxicity and high stability and solubility. Preliminary experimental results using our dyes and literature studies indicate several promising materials. Future synthetic efforts will be directed to commercial development of the optimum dye for the staining.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    PTHB
  • Study Section Name
    Pathology B Study Section
  • Organization Name
    MOLECULAR PROBES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    EUGENE
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    97402
  • Organization District
    UNITED STATES